Given the specific features of HER2-OE BC, namely the phenotype and behavior of the immune infiltrate and the patients’ response to anti-HER2 therapy, it is fundamental to develop reliable tools to study the immune modulation promoted by anti-HER2 targeting agents in an all-human setting. The gene discussed is ERBB2; the disease is breast cancer.